Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole once-weekly 48 mg versus placebo in acute schizophrenia
jRCT2061220006Recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jul 2022
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in schizophrenia comparing Brexpiprazole once-weekly 48 mg with Placebo (2 arms). Primary endpoint: Mean change from baseline in Positive and Negative Syndrome Scale total score at Week 7. Started Jul 2022; status: recruiting.
02
Drugs
brexpiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2061220006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220006.